AxoGen, Inc.

NASDAQ:AXGN

Medical - Devices

Healthcare
$56.95 +0.56%

+$0.25 today

Market cap
$3.40B
Beta
1.12
P/E (TTM)
-73.4
EPS (TTM)
-$0.61
52W Low $9.35High $45.83

Volume 2.11M

Average 1.08M

AXGN EBITDA Margin

EBITDA as a percentage of revenue.

AxoGen, Inc.NASDAQ: AXGN

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin narrows to 5.3%

EBITDA Margin was 5.3% in Q3 FY2026, down 15.9 pp from a year earlier. On a trailing-twelve-month basis it was -8.0%, down 18.0 pp year over year. Over 3 fiscal years it widened by 17.0 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 17.6% for the fiscal year ending Dec 2026, up from 0.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
5.3%+5.3 pp QoQ
Last fiscal yearDec 2025
0.1%-3.2 pp YoY
LTMSep 2026
-8.0%-18.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-15.9 pp+30.5 pp+46.5 pp
1 year-3.2 pp+17.5 pp+20.6 pp
3 years+17.0 pp+18.3 pp+1.3 pp
5 years+21.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
0.1%
Year-over-year change
-3.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How AXGN compares with its peers on the latest reported figures

  • AXGN's LTM Sep 2026 EBITDA Margin of -8.0% is the 5th highest of the 7 companies compared; the peer median is 8.5%.
  • Its year-over-year change of -18.0 pp is the 6th highest of 7, against a peer median of +6.4 pp.
  • Over three fiscal years its change of +17.0 pp compares with a peer median of +22.5 pp.
AXGN Competitors Peer median
EBITDA Margin for AXGN and competitors
Company Period LTM level YoY 3-year change
BSEMBioStem Technologies, Inc.LTM Jun 202636.5% +28.9 pp+93.8 pp
MDXGMiMedx Group, Inc.LTM Mar 202614.7% -3.3 pp+23.8 pp
XTNTXtant Medical Holdings, Inc.LTM Mar 20269.7% +12.3 pp+21.2 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 20267.3% +8.1 pp+4.2 pp
AXGNAxoGen, Inc.LTM Sep 2026-8.0% -18.0 pp+17.0 pp
TELATELA Bio, Inc.LTM Jun 2026-41.4% +4.7 pp+54.0 pp
HUMAHumacyte, Inc.LTM Mar 2026-3956.7% -3182.9 pp-1247.4 pp
Peer median (excluding AXGN) 8.5%+6.4 pp+22.5 pp

Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue127.36M138.58M159.01M187.34M225.21M
Cost of Revenue22.93M29.78M37.14M45.36M57.86M
Gross Profit104.43M108.81M121.87M141.98M167.35M
Gross Margin82.0%78.5%76.6%75.8%74.3%
Research & Development24.18M25.63M27.34M27.77M32.89M
Selling, General & Admin105.67M112.89M115.99M117.5M142.32M
Operating Expenses129.84M138.52M143.33M145.26M175.2M
Depreciation & Amortization4.74M4.85M5.55M7.84M8.19M
EBITDA(20.89M)(23.47M)(13.33M)6.08M192K
EBITDA Margin-16.4%-16.9%-8.4%3.2%0.1%
Operating Income(25.42M)(29.71M)(21.46M)(3.29M)(7.85M)
Operating Margin-20.0%-21.4%-13.5%-1.8%-3.5%
Interest Income00000
Interest Expense1.36M624K2.84M8.21M7.7M
Other Income / Expenses(1.57M)759K(254K)(6.68M)(7.85M)
Income Before Tax(26.99M)(28.95M)(21.72M)(9.96M)(15.7M)
Pre-Tax Margin-21.2%-20.9%-13.7%-5.3%-7.0%
Income Tax Expense00000
Net Income(26.99M)(28.95M)(21.72M)(9.96M)(15.7M)
Net Margin-21.2%-20.9%-13.7%-5.3%-7.0%
EPS (Basic)(0.65)(0.69)(0.51)(0.23)(0.34)
EPS (Diluted)(0.65)(0.69)(0.51)(0.23)(0.34)
Weighted Avg Shares41.22M42.08M42.88M44.26M46.05M
Weighted Avg Shares (Diluted)41.22M42.08M42.88M44.26M46.05M

AxoGen, Inc.

NASDAQ:AXGN

Intrinsic Alpha fair value

Locked

Current Price

$56.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.